Phase II Trial Of CQS (NSC 339004) In Platinum-Refractory Small Cell Lung Cancer
OBJECTIVES: I. Determine the efficacy of chloroquinoxaline sulfonamide in patients with
platinum-refractory small cell lung cancer. II. Determine the toxic effects of this drug in
these patients.
OUTLINE: Patients receive chloroquinoxaline sulfonamide IV over 1 hour once a week for 4
weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable
toxicity. Patients are followed until death.
PROJECTED ACCRUAL: A total of 12-38 patients will be accrued for this study within 12-18
months.
Interventional
Primary Purpose: Treatment
Primo N. Lara, MD
Study Chair
University of California, Davis
United States: Federal Government
00104
NCT00008372
December 2000
September 2002
Name | Location |
---|---|
Cancer Center and Beckman Research Institute, City of Hope | Duarte, California 91010-3000 |
USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles, California 90033-0804 |
University of California Davis Cancer Center | Sacramento, California 95817 |